PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.18%
R&D growth above 1.5x AXSM's 15.67%. Michael Burry would check for spending discipline.
22.12%
G&A growth while AXSM reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.03%
Operating expenses growth above 1.5x AXSM's 8.07%. Michael Burry would check for inefficiency.
35.03%
Total costs growth above 1.5x AXSM's 4.54%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
14.84%
D&A growth above 1.5x AXSM's 8.65%. Michael Burry would check for excessive investment.
-35.35%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.72%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-37.55%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.55%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-34.88%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-34.88%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
2.03%
Share count reduction below 50% of AXSM's 0.34%. Michael Burry would check for concerns.
2.03%
Diluted share reduction below 50% of AXSM's 0.34%. Michael Burry would check for concerns.